Dr Anthony Hall (Tony) graduated from King’s College London with first class honours in physiology and pharmacology before going on to study medicine at the Royal Free Hospital. He joined the pharmaceutical industry in 1994 and has spent many years working on the development of drugs for rare diseases. From 2014 to 2015 Tony worked at Prosensa / Biomarin on the development of antisense oligonucleotides for the treatment of Duchenne muscular dystrophy. He currently works at Mereo BioPharma as Therapeutic Area Head Orphan Diseases.
Tony speaks regularly at rare diseases conferences and is author of a number of articles and book chapters on orphan drugs. Together with the charity Findacure’s co-founder, he has recently published a book entitled “The Patient Group Handbook: A Practical Guide for Research and Drug Development”. Tony sits on the Scientific Advisory Board of the rare diseases charities Duchenne UK and Findacure.